Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Comment on “Patient perspectives on Peyronie’s disease: results of poststudy interviews from a phase 2 trial of collagenase clostridium histolyticum”

International Journal of Impotence Research volume 31, page 300 (2019)Cite this article

Subjects

In this article, Kaminetsky et al. [1] report on results of poststudy interviews in a small cohort of 45 patients who underwent a phase 2b trial of intralesional Collagenase Clostridium Histolyticum (CCH). Interviews consisted of hour-long cognitive debriefing sessions at the outset of the study to better characterize patients’ experiences prior and following treatment with CCH. Pre-, in- and post-trial assessments were not dynamically collected, but were rather obtained retroactively through telephone interviews after the study had been completed. These included subjective assessments of bother, symptoms and treatment satisfaction, as well as PDQ domain scores. Patients were considered “responders” if they reported at least “improved in a small but important way” after CCH therapy on the Global Assessment of the PDQ.

As would be expected with most Peyronie’s disease patients, they mostly complained of penile angulation, shortening, pain, change in shape, and presence of plaque, and were most distressed by penile curvature, difficulty with intercourse and their effects on relationship [2]. Post trial, vaguely 50% of patients reported improvements in curvature and symptom bother, with 70% being labeled as “responders”. Overall, 22% reported a positive impact of treatment on their relationship, with 56% and 11% of patients and partners reporting improved sexual encounters, respectively, which is lower than previously reported [3].

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Kaminetsky J, Gittleman M, Kaufman GJ, Smith TM, Jordan GH. Patient perspectives on Peyronie’s disease: results of poststudy interviews from a phase 2 trial of collagenase clostridium histolyticum. IJIR. 2018.

  2. Serefoglu EC, Smith TM, Kaufman GJ, Liu G, Yafi FA, Hellstrom WJG. Factors associated with erectile dysfunction and the peyronie’s disease questionnaire in patients with Peyronie disease. Urology. 2017;107:155–60.

    Article  Google Scholar 

  3. Anaissie J, Yafi FA, Traore EJ, Sikka SC, Hellstrom WJ. Survey of patient and partner satisfaction following collagenase Clostridium histolyticum treatment for Peyronie’s disease. Andrology. 2017;5:274–7.

    Article  CAS  Google Scholar 

  4. Gelbard M, Goldstein I, Hellstrom WJ, McMahon CG, Smith T, Tursi J, Jones N, Kaufman GJ, Carson CC 3rd. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol. 2013;190:199–207.

    Article  CAS  Google Scholar 

  5. Anaissie J, Yafi FA, DeLay KJ, Traore EJ, Sikka SC, Hellstrom WJG. Impact of number of cycles of collagenase clostridium histolyticum on outcomes in patients with Peyronie’s disease. Urology. 2017;100:125–30.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, University of California, Irvine, CA, USA

    Faysal A. Yafi

Authors
  1. Faysal A. Yafi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Faysal A. Yafi.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yafi, F.A. Comment on “Patient perspectives on Peyronie’s disease: results of poststudy interviews from a phase 2 trial of collagenase clostridium histolyticum”. Int J Impot Res 31, 300 (2019). https://doi.org/10.1038/s41443-018-0040-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41443-018-0040-8

Search

Advanced search

Quick links